© 2020 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Melanoma
Patients in CheckMate 067 Demonstrate Durable Complete Responses
May 22, 2020
Georgina V. Long, BSc, PhD, MBBS, discusses the response rates in the CheckMate 067 trial, which evaluated the combination of ipilimumab and nivolumab in patients with advanced melanoma.
Pembrolizumab Plus Interleukin-12 Shows Activity in Metastatic Melanoma
May 08, 2020
"Combining pembrolizumab with Tavo electroporation improved responses for these patients who were predicted to have very poor responses to single-agent immune checkpoint inhibition."
Engineered Cellular Therapies Enter Treatment Landscape of Melanoma
May 04, 2020
In an interview with Targeted Oncology, Bruce L. Levine, PhD, discussed hot topics in the treatment landscape of melanoma, including the development of chimeric antigen receptor T and NK cells.
Combination Regimens Inspire Hope for the Treatment of Melanoma
May 04, 2020
In an interview with Targeted Oncology, Michael A. Davies, MD, PhD, discussed the current treatment landscape of melanoma and the recent advances that have provided a great level of optimism to what has been known to be a very challenging cancer setting.
Vemurafenib/Cobimetinib Plus Atezolizumab Combo Improves PFS in Advanced Melanoma
May 03, 2020
"Atezolizumab combined with vemurafenib and cobimetinib showed a statistically significant and clinically meaningful in progression-free survival via investigator assessment when compared with placebo plus vemurafenib and cobimetinib."
Weber Evaluates the Role of Neoadjuvant and Adjuvant Immunotherapy in Melanoma
April 22, 2020
In an interview with Targeted Oncology, Jeffrey S. Weber, MD, PhD, discussed the role of neoadjuvant and adjuvant therapy for the treatment of patients with melanoma. He also highlighted the role of immunotherapy, as well as other types of therapy, in this treatment landscape.
Evaluating Prognosis of Patients With Ocular Melanoma
April 17, 2020
Ragini Kudchadkar, MD, discusses the overall prognosis of patients with ocular melanoma.
Rarity of Uveal Melanoma Challenges Clinical Trial Enrollment
April 04, 2020
In an interview with Targeted Oncology, Richard D. Carvajal, MD, discussed the challenges of conducting clinical trials for the treatment of patients with uveal melanoma, as well as the excitement surrounding 2 potential therapies in this space.
Targeted Therapies Contribute to Significant Decline in Melanoma-Related Mortality
March 24, 2020
The mortality rate for cutaneous melanoma was significantly reduced between 2013 to 2016 as a result of new targeted therapies for metastatic disease, according to a recent report in the American Journal of Public Health. It is the largest death decline ever recorded for skin cancer.
Adjuvant Ipilimumab Dose Improves Survival Benefit for Resected High-Risk Melanoma
March 17, 2020
Adjuvant ipilimumab at a dose of 3 mg/kg demonstrated a survival benefit in patients with resected high-risk melanoma compared with high-dose interferon alfa-2b, according to the findings for a phase III E1609 clinical trial from the North American Intergroup.